BioPharmX and Wellman Center for Photomedicine Researchers Develop Optical Imaging Technique to Visualize Drug Delivery.
M2 PHARMA-October 12, 2017-BioPharmX and Wellman Center for Photomedicine Researchers Develop Optical Imaging Technique to Visualize Drug Delivery
(C)2017 M2 COMMUNICATIONS
- Menlo Park, California-based specialty pharmaceutical company BioPharmX Corp. (NYSE MKT: BPMX) researchers were part of a national scientific team that developed an innovative way to use nonlinear optical imaging to confirm the efficiency and quantity of the delivery of new drugs, the company said.
A presentation at the 2017 Fall Clinical Dermatology Conference will show how researchers from BioPharmX and the Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School used a suite of imaging techniques in what is called "Pharmacokinetic Tomography" to confirm highly localised delivery of BPX-01, BioPharmX's topical, hydrophilic gel formulation of minocycline for the treatment of acne vulgaris, to the area of the skin where acne develops.
This is the first time this imaging approach was used to confirm substantial minocycline uptake in the epidermis and hair follicle, as well as in the sebaceous gland 24 hours after a single dose application.
A poster presentation, entitled "Visualization of Cutaneous Distribution of Minocycline of a Topical Gel in Human Facial Skin with Two-Photon Excited Fluorecence Lifetime Imaging Microscopy and Phasor Analysis," will also be on display at the Fall Clinical conference in Las Vegas Oct. 12-15.
The nonlinear optical imaging technique developed by this team enables the use of the natural fluorescence of the drug when "excited" with ultrashort (femtosecond) laser pulses.
BioPharmX seeks to provide products through proprietary platform technologies for prescription, over-the-counter, and supplement applications in the health and wellness markets, including dermatology and women's health.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Caris Life Sciences' Precision Oncology Alliance Adds St. Jude Crosson Cancer Institute.|
|Next Article:||Ardelyx Study of Tenapanor for IBS-C Hits Demonstrates Ability to Normalize Bowel Function.|